ORLANDO, Fla.—When added to a regimen of carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma, daratumumab significantly extends time to progression or death, according to results from the phase 3 CANDOR trial.
The benefit of daratumumab (Darzalex, Janssen) is attributed to its ability “to deepen the clinical response,” according to Saad Z. Usmani, MD, the director of clinical research in hematologic malignancies at the Levine Cancer